09:54 AM EST - Bausch Health Companies Inc. : Said its Salix Pharmaceuticals subsidiary has entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. Bausch Health Companies Inc.
shares T.BHC are trading down $0.31 at $30.74.
